APC Anti-CD45.1 antibody [A20] (ab25348)
Key features and details
- APC Mouse monoclonal [A20] to CD45.1
- Suitable for: Flow Cyt
- Reacts with: Mouse
- Conjugation: APC. Ex: 645nm, Em: 660nm
- Isotype: IgG2a
Related conjugates and formulations
Overview
-
Product name
APC Anti-CD45.1 antibody [A20]
See all CD45.1 primary antibodies -
Description
APC Mouse monoclonal [A20] to CD45.1 -
Host species
Mouse -
Conjugation
APC. Ex: 645nm, Em: 660nm -
Tested applications
Suitable for: Flow Cytmore details -
Species reactivity
Reacts with: Mouse -
Immunogen
Tissue, cells or virus corresponding to CD45.1. SJL mouse thymocytes and splenocytes
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C. Do Not Freeze. Store undiluted. -
Storage buffer
pH: 7.20
Preservative: 0.09% Sodium azide
Constituents: 0.1% Gelatin, 0.14% Monobasic dihydrogen sodium phosphate, 0.87% Sodium chloride -
Concentration information loading...
-
Purity
Affinity purified -
Clonality
Monoclonal -
Clone number
A20 -
Isotype
IgG2a -
Light chain type
kappa -
Research areas
Associated products
-
Alternative Versions
- PerCP/Cy5.5® Anti-CD45.1 antibody [A20] (ab210237)
- violetFluor™ 450 Anti-CD45.1 antibody [A20] (ab241939)
- FITC Anti-CD45.1 antibody [A20] (ab24917)
- Cy5 ® Anti-CD45.1 antibody [A20] (ab24982)
- Biotin Anti-CD45.1 antibody [A20] (ab25011)
- Anti-CD45.1 antibody [A20] (ab25078)
- PE/Cy5® Anti-CD45.1 antibody [A20] (ab25349)
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab25348 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Flow Cyt |
Use at an assay dependent concentration.
|
Notes |
---|
Flow Cyt
Use at an assay dependent concentration. |
Target
-
Relevance
CD45 is an essential regulator of leukocyte activation and development, and is now known to be a protein tyrosine phosphatase, e.g. CD45 is able to dephosphorylate the Src family of protein kinases. This activity is now known to be required for signal transduction induced by T and B cell antigen receptor engagement, cytokine signaling and Fc receptor stimulation. The functional state of CD45 also has a pronounced effect on lymphocyte development. CD45 exists in multiple forms, such as the restricted variants and as allelic forms CD45.1/Ly5.1 and CD45.2/Ly5.2. The former arises as a result of alternative splicing of different exons. The specificity of antibodies to CD45.1 and CD45.2 has been exploited in studies in which resolution of donor and recipient cells is essential, such as in gene therapy or bone marrow transplantation. -
Cellular localization
Type I membrane protein. -
Database links
- Entrez Gene: 19264 Mouse
- SwissProt: P06800 Mouse
-
Alternative names
- B220 antibody
- CD45 antibody
- CD45 antigen antibody
see all
Images
Datasheets and documents
-
SDS download
-
Datasheet download
References (3)
ab25348 has been referenced in 3 publications.
- Patino E et al. Iron therapy mitigates chronic kidney disease progression by regulating intracellular iron status of kidney macrophages. JCI Insight 8:N/A (2023). PubMed: 36394951
- Mardiney M & Malech HL Enhanced engraftment of hematopoietic progenitor cells in mice treated with granulocyte colony-stimulating factor before low-dose irradiation: implications for gene therapy. Blood 87:4049-56 (1996). PubMed: 8639760
- Vallera DA et al. The role of host T cell subsets in bone marrow rejection directed to isolated major histocompatibility complex class I versus class II differences of bm1 and bm12 mutant mice. Transplantation 57:249-56 (1994). PubMed: 7906058